|
KMID : 1039620220120050340
|
|
Korean Journal of Family Practice
2022 Volume.12 No. 5 p.340 ~ p.345
|
|
|
Effectiveness of Regdanvimab and Remdesivir in Patients with COVID-19 at a Single Hospital
|
|
Kim Sun-Mo
Jeong Hwee-Soo
Lim Ji-Sun
Lee Ji-Yong
Ko Jae-Hoon
Suh Sang-Joon
Yoon Young-Joo
|
|
|
Abstract
|
|
|
Background: This study examined the clinical effectiveness of regdanvimab and remdesivir in patients hospitalized with COVID-19.
Methods: This retrospective cross-sectional study analyzed the medical records of 128 patients hospitalized with COVID-19 at a hospital in Seoul from 17th December 2020 to 16th February 2022. Demographic data, the hospitalization period, presence of pneumonia on chest X-ray, oxygen treatment period while hospitalized, and discharge place were collected for all patients.
Results: Of the total number of patients, 112 (87.5%) received only regdanvimab, 13 (10.2%) received regdanvimab plus remdesivir, and 3 (2.3%) received neither treatment (the non-medicine group). The hospital stay was significantly shorter in those who received regdanivimab alone or regdanivimab plus remdesivir (9.1±3.1 and 11.6±3.4 days, respectively) compared with the non-medicine group (27.0±14.7 days; P=0.002). The duration of oxygen treatment via nasal prongs in the three groups, i.e., the non-medicine group, those who received regdanivimab alone, and those who received regdanivimab plus remdesivir, was 22.0±19.2, 0.5±2.0, and 3.5±5.7 days, respectively, and was significantly shorter in those who received drug therapy (P=0.031). The rate of discharge to home was also considerably higher in those who received regdanivimab alone or regdanivimab plus remdesivir (97.3% and 100.0%) than in the non-medicine group (33.3%) (P=0.004). Medication use for treating COVID-19 reduced transfer rates to tertiary hospitals and mortality (odds ratio, 0.045; 95% confidence interval, 0.002?0.955; P=0.047).
Conclusion: Use of COVID-19 medicines shortened the hospitalization period and duration of oxygen treatment in inpatients and significantly lowered the rates of transfer to tertiary hospitals and death after treatment.
|
|
|
KEYWORD
|
|
|
COVID-19, Regdanvimab, Remdesivir, Treatment Outcome
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|
|